Primary chemotherapy for breast cancer: hope or hype?
Morrow, M.
Seminars in Oncology 25(2 Suppl 3: 1-2
1998
ISSN/ISBN: 0093-7754 PMID: 9566200 Document Number: 490383
Document emailed within 1 workday
Related Documents
Toh, H.C. 2000: High dose chemotherapy in breast cancer--a thin red line between hype and hope Singapore Medical Journal 41(2): 86-88Janssen, J.J.W.M.; Huijgens, P.C. 2006: Stem cells: hype and hope Nederlands Tijdschrift Voor Geneeskunde 150(27): 1494-1496
McArthur, H.L. 2016: Checkpoint inhibitors in breast cancer: hype or promise? Clinical Advances in Hematology and Oncology: H&o 14(6): 392-395
Feussner, H.; Wilhelm, D.; Meining, A.; Schneider, A.; Fiolka, A.; Can, S.; Friess, H. 2009: Notes: technical aspects - hype or hope? Surgical Technology International 18: 26-35
Simon, D. 1992: Steroids in alcohol hepatitis: hope or hype? American Journal of Gastroenterology 87(12): 1883-1884
Takada, M.; Toi, M. 2007: Primary systemic chemotherapy for breast cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 34(11): 1730-1734
Auclerc, G.; Borel, C.; Khayat, D.; Soubrane, C.; Weil, M. 1992: Primary chemotherapy in the treatment of breast cancer Annales de Chirurgie Plastique et Esthetique 37(6): 663-669
Li, J-Feng.; Ouyang, T.; Wang, T-Feng.; Lin, B-Yao. 2004: Neoadjuvant chemotherapy for primary breast cancer Zhonghua Zhong Liu Za Zhi 26(8): 493-495
Lee, J. 2014: Hype or hope for diabetes mobile health applications? Diabetes Research and Clinical Practice 106(2): 390-392
Harris, L.; Swain, S.M. 1996: The role of primary chemotherapy in early breast cancer Seminars in Oncology 23(1 Suppl 2: 31-42
Kang, G. 2010: HPV vaccines: separating real hope from drug company hype Indian Journal of Medical Ethics 7(1): 56-57
Jacobs, J.W.G.H.; Huizinga, T.W.J.; Bijlsma, J.W.J.H.; van der Helm-van Mil, A.H.M. 2009: Progress due to genetic research on rheumatoid arthritis: hype or hope? Nederlands Tijdschrift Voor Geneeskunde 153: A206
Conti, F.; Sergi, D.; Foggi, P.; Abbate, M.I.; Lopez, M. 2007: New combination chemotherapy regimens in the primary treatment of operable breast cancer La Clinica Terapeutica 158(1): 55-75
Ohta, K.; Dohden, K.; Morishita, M.; Hayashi, H.; Hattori, M.; Hosokawa, O.; Morita, M.; Kaizaki, Y.; Kiya, T. 2006: Clinical examination of safety and effectiveness of primary chemotherapy with CEF followed by docetaxel in preoperative breast cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 33(2): 199-202
Van Rie, A.; Page-Shipp, L.; Scott, L.; Sanne, I.; Stevens, W. 2010: Xpert(®) MTB/RIF for point-of-care diagnosis of TB in high-HIV burden, resource-limited countries: hype or hope? Expert Review of Molecular Diagnostics 10(7): 937-946
Niu, Z.-H.; Wang, Y.; Chun, B.; Li, C.-X.; Wu, L. 2013: Secretory clusterin (sCLU) overexpression is associated with resistance to preoperative neoadjuvant chemotherapy in primary breast cancer European Review for Medical and Pharmacological Sciences 17(10): 1337-1344
Warm, M.; Kates, R.; Mallmann, P.; Dick, Mèlle.; Nawroth, F.; Harbeck, N.; Paepke, S.; Thomas, A. 2007: Impact of tumor biological factors on response to pre-operative epirubicin and paclitaxel chemotherapy in primary breast cancer Anticancer Research 27(2): 1031-1038
Clapperton, G. 1991: Breast cancer. Hope and charity Nursing Times 87(35): 56
Stamatovic, L.; Susnjar, S.; Gavrilovic, D.; Minic, I.; Ursulovic, T.; Dzodic, R. 2018: The influence of breast cancer subtypes on the response to anthracycline neoadjuvant chemotherapy in locally advanced breast cancer patients Journal of Buon: Official Journal of the Balkan Union of Oncology 23(5): 1273-1280
Walker, A.R.; Walker, B.F. 1993: Breast cancer avoidance--is there really a strategy of hope? South African Medical Journal 83(9): 631-632